For investors in healthcare stocks, 1995 was a much-needed shotin the arm that remedied a three-year period of falling shareprices. An annual survey by WDI Capital Markets of Hilton Head,SC, saw a strong surge in share prices among healthcare
For investors in healthcare stocks, 1995 was a much-needed shotin the arm that remedied a three-year period of falling shareprices. An annual survey by WDI Capital Markets of Hilton Head,SC, saw a strong surge in share prices among healthcare companieslast year. Vendors of cardiac instruments led the charge in stockvaluation growth, although manufacturers of medical imaging devicesturned in a strong performance as well.
For the year, overall healthcare industry share prices leaped40.1%, compared with a 4.7% decline in 1994. Share prices dropped9.4% in 1993 and 10.6% in 1992.
Among public imaging device companies, stock prices trackedby WDI climbed 75.8% in 1995, compared with a lackluster gainof 1.2% in 1994. ThermoTrex led the segment with share-price growthof 270%, while bone densitometry firm Hologic jumped 173%. Othervendors turning in strong performances for the year were bonedensitometry vendor Lunar, up 129%; image-guided catheter manufacturerEndosonics, up 122%; x-ray vendor Fischer Imaging, up 85%; andnuclear medicine firm ADAC Laboratories, up 55%.
Imaging services firms also enjoyed rising stock valuations,according to WDI's survey. Share prices in the segment rose anaverage of 52.2% for the year.
In other WDI news, the investment and advisory firm announcedthat former Fischer Imaging executive Robert Cascella has joinedthe company as president.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.